A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.

@article{Serruys1999ARP,
  title={A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.},
  author={P. W. Serruys and David P. Foley and Graham Jackson and Hans J R M Bonnier and Carlos M Macaya and Mathy Vrolix and Angelo Branzi and James Michael Shepherd and Harry Suryapranata and Pim J. de Feyter and Rein Melkert and G-A van Es and Pascal Pfister},
  journal={European heart journal},
  year={1999},
  volume={20 1},
  pages={58-69}
}
BACKGROUND The 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors competitively inhibit biosynthesis of mevalonate, a precursor of non-sterol compounds involved in cell proliferation. Experimental evidence suggests that fluvastatin may, independent of any lipid lowering action, exert a greater direct inhibitory effect on proliferating vascular myocytes than other statins. The FLARE (Fluvastatin Angioplasty Restenosis) Trial was conceived to evaluate the ability of fluvastatin… CONTINUE READING